About Euticals
Euticals is a Healthcare company based in Milano (Italy) founded in 1984, and was acquired by Curia in May 2016. APIs, custom synthesis, and fine chemicals are developed and manufactured. Euticals has completed 1 acquisition, including Archimica. Its chief executive, as recorded, is Margalit Fine. Euticals offers products and services including Cytarabine, Hydroxyurea, Mianserin, and Sucralfate. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and API Production. Its legal entity is Archimica S.p.A.
Company details
Euticals was founded in 1984 and is based in Milano, Italy, with operations in the pharmaceutical sector. Plants are located in Italy, France, Germany, and the USA. A portfolio of over 200 API products is maintained, covering areas such as anti-inflammatory, anticancer, anti-infective, cardiovascular, and CNS therapies. Eighteen fine chemical products are also offered. The company was acquired by Albany Molecular Research on May 5, 2016.
- Headquarters Milano, Italy
- Stage Acquired
- SectorsHealthcare
- Website euticals.com
- Social LinkedIn
- Acquired by Curia (May 2016)
- Legal Name Archimica S.P.A.
Products & Services of Euticals
Euticals offers a comprehensive portfolio of products and services, including Cytarabine, Hydroxyurea, Mianserin, and Sucralfate.
Nucleoside analogue for cancer treatment applications
Modified urea used in oncology medications
Tetracyclic compound for psychiatric treatments
Saccharose sulfate for gastrointestinal therapies
Funding Insights of Euticals
- Total Rounds 2
- Investors Count 2
All 2 funding rounds of Euticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2012 | Private Equity Round | – | – | ||
| Feb 2011 | Private Equity Round | – | – |
4 investors in total: 4 institutional.
Investors in Euticals
Euticals has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Curia, Clessidra Private Equity and Private Equity Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Clessidra Private Equity is focused on mid-cap company investments. | clessidraprivateequity.it | Milan, Italy | ||
Private Equity Partners is engaged in private equity and venture capital investments. | 1989 | privateequitypartners.com | Milan, Italy | |
| mcpinvest.lu | ||||
Drug research, development, testing, and consulting services are provided. | 1991 | curiaglobal.com | Albany, United States |
Investor details for Euticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Euticals
1 people are tracked at Euticals (1 in leadership).
| Name | Role | Group |
|---|---|---|
Margalit Fine | CEO | Leadership |
Complete people profiles for Euticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Euticals
Euticals has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Archimica.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Develops nucleic acid analysis tools for research and clinical diagnostics applications | archimica.com | Sandycroft, United Kingdom | 1999 | Jan 2011 | •••• |
Complete acquisition details for Euticals
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Euticals
6 dated milestones of Euticals across 32 years, from founding to its latest funding, stage changes and deals.
Web traffic of Euticals
Websites that share an audience with Euticals (euticals.com).
Websites whose visitors overlap most with Euticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| clinicalconnection.com | 100% | #127,111 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Euticals
Euticals was founded in 1984 and raised its 1st funding round 27 years after it was founded.
Euticals is headquartered in Milano, Italy.
Margalit Fine is the CEO of Euticals, as recorded in our data.
Euticals was founded in 1984 and is based in Milano, Italy, with operations in the pharmaceutical sector. Plants are located in Italy, France, Germany, and the USA. A portfolio of over 200 API products is maintained, covering areas such as anti-inflammatory, anticancer, anti-infective, cardiovascular, and CNS therapies. Eighteen fine chemical products are also offered. The company was acquired by Albany Molecular Research on May 5, 2016.
Euticals offers Cytarabine, Hydroxyurea, Mianserin, and Sucralfate.
Euticals has made 1 acquisition, including Archimica.
Euticals has 4 investors. Key investors include Curia, Clessidra Private Equity, Private Equity Partners, and Mandarin Capital Partners.
Euticals operates through Archimica S.P.A..
Yes. Euticals was acquired by Curia in May 2016.